Glaukos Corporation (GKOS) EPS Estimated At $-0.14

October 13, 2018 - By Peter Kolinski

Glaukos Corporation (NYSE:GKOS) Logo

Analysts expect Glaukos Corporation (NYSE:GKOS) to report $-0.14 EPS on November, 6.They anticipate $0.18 EPS change or 450.00 % from last quarter’s $0.04 EPS. After having $-0.15 EPS previously, Glaukos Corporation’s analysts see -6.67 % EPS growth. The stock increased 3.99% or $2.26 during the last trading session, reaching $58.86. About 437,127 shares traded. Glaukos Corporation (NYSE:GKOS) has risen 54.53% since October 14, 2017 and is uptrending. It has outperformed by 38.91% the S&P500.

Glaukos Corporation (NYSE:GKOS) Ratings Coverage

Among 4 analysts covering Glaukos (NYSE:GKOS), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Glaukos had 8 analyst reports since April 30, 2018 according to SRatingsIntel. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, September 5 report. As per Thursday, June 21, the company rating was downgraded by J.P. Morgan. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, August 3. The company was downgraded on Tuesday, July 10 by BMO Capital Markets. The stock has “Overweight” rating by JP Morgan on Wednesday, August 29. The stock has “Outperform” rating by BMO Capital Markets on Friday, June 1. BMO Capital Markets maintained the stock with “Market Perform” rating in Thursday, August 30 report.

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. The company has market cap of $2.08 billion. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. It currently has negative earnings. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.

Glaukos Corporation (NYSE:GKOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>